Current Report Filing (8-k)
April 22 2020 - 09:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): April 22, 2020
CORMEDIX
INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-34673
|
|
20-5894890
|
(State
of other jurisdiction of
incorporation
or organization)
|
|
(Commission
File Number)
|
|
(I.R.S.
Employer
Identification
No.)
|
400
Connell Drive, Suite 5000
Berkeley
Heights, NJ
|
|
07922
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (908) 517-9500
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2, below):
☐
|
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Exchange Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
stock, $0.001 par value
|
|
CRMD
|
|
NYSE
American LLC
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
8.01. Other Events.
On
April 22, 2020, CorMedix Inc. (the “Company”) issued a press release to announce that the Company completed the previously
announced sale of $5.5 million of the total $6.0 million of its available tax benefits to an unrelated, profitable New Jersey
corporation pursuant to its application to participate in the New Jersey Technology Business Tax Certificate Transfer (NOL) program
for State Fiscal Year 2019. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated
herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
CORMEDIX
INC.
|
|
|
|
Date: April 22,
2020
|
By:
|
/s/
Khoso
Baluch
|
|
Name:
|
Khoso
Baluch
|
|
Title:
|
Chief
Executive Officer
|
2
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Feb 2024 to Mar 2024
CorMedix (AMEX:CRMD)
Historical Stock Chart
From Mar 2023 to Mar 2024